SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001140361-22-022594
Filing Date
2022-06-10
Accepted
2022-06-10 16:15:26
Documents
1
Group Members
DAVID C. OTTO. ANDREAS HALVORSENROSE S. SHABETVIKING GLOBAL EQUITIES II LPVIKING GLOBAL EQUITIES MASTER LTD.VIKING GLOBAL PERFORMANCE LLCVIKING LONG FUND GP LLCVIKING LONG FUND MASTER LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13G brhc10038648_sc13g.htm SC 13G 351900
  Complete submission text file 0001140361-22-022594.txt   353903
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-37761 | Film No.: 221009060
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 55 RAILROAD AVENUE GREENWICH CT 06830
Business Address 55 RAILROAD AVENUE GREENWICH CT 06830 212-672-7050
VIKING GLOBAL INVESTORS LP (Filed by) CIK: 0001103804 (see all company filings)

IRS No.: 134055118 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G